Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Lymphomas: CD is associated with classic Hodgkin ... supporting a neoplastic continuum from CD to malignancy. ・ Indolent T/B-lymphoblastic proliferation: Seen in CD with clusters of immature ...

not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B–cell lymphoma (HGBL), after two or more lines of systemic therapies.” It is in the same class as ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 10.66%, which has investors questioning if this is ...

The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; COPAXONE to treat patients with relapsing ...

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders ...

It’s also picked its first FDA approval for Revlimid in combination with Roche’s blockbuster Rituxan (rituximab) in indolent non-Hodgkin’s lymphoma (NHL). “I’m looking forward to working ...